Antiarrhythmic drugs: From mechanisms to clinical practice

Heart

Volumn 84, Issue 3, 2000, Pages 339-346

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CISAPRIDE; CODEINE; DIGITALIS; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; LIDOCAINE; METOPROLOL; MEXILETINE; MORACIZINE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; RIFAMPICIN; RITONAVIR; SOTALOL; TIMOLOL; TOCAINIDE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; PRIORITY JOURNAL; QT INTERVAL; SINUS NODE DISEASE; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; ION CHANNELS; PATIENT SELECTION; SODIUM CHANNELS; TORSADES DE POINTES;

EID: 0033823284     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Vaughan Williams EM. Classification of antiarrhythmic action Handbook of Experimental Pharmacology 1989;89:45-62. • The Vaughan Williams approach to classification, developed in the late 1960s, remains widely used by clinical cardiologists, primarily because of its ability to predict antiarrhythmic drug toxicity.
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51 • The "Sicilian Gambit" proposed that definition of arrhythmia mechanisms would allow identification of specific "vulnerable parameters" that available or new drugs could target to best suppress arrhythmias.
3. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the European Society of Cardiology. Eur Heart J 1999;20:174-95 (also published in Circulation 1999;99:518-528, 674-81) • An in-depth summary of current thinking on the molecular and genetic basis of arrhythmias and how these might form the basis for new treatments.
4. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the European Society of Cardiology. Eur Heart J 1999;20:174-95 (also published in Circulation 1999;99:518-528, 674-81) • An in-depth summary of current thinking on the molecular and genetic basis of arrhythmias and how these might form the basis for new treatments.
5. Stambler BS, Wood MA, Ellenbogen KA, et al, the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
6. Roden DM, Lazzara R, Rosen MR, et al, the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long QT syndrome: current knowledge, gaps, and future directions. Circulation 1996;94:1996-2012.
7. Crijns HJ, van Gelder IS, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988;62:1303-6.
8. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12. • The cardiac arrhythmia suppression trial (CAST) was a landmark study that defined the phenomenon of increased mortality during long term antiarrhythmic drug treatment. CAST has had huge implications for use of available drugs, development of new drugs, and the use of the large randomised placebo controlled trial to evaluate "hard end points" (such as mortality) during drug treatment, rather than relying on drug effects on surrogates such as extrasystole suppression.
9. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential, but a long way to go: reduced effectiveness and dangers of reverse use-dependence. Circulation 1990;81:686-90.
10. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 1999;341:1882-90.
11. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990;82:1106-16. • This meta-analysis indicated that while quinidine appears more effective than placebo in maintaining sinus rhythm, it is associated with a > 3 fold increase in mortality. While the study has been criticised because many of the original reports were published before concentration monitoring or awareness of the digoxin-quinidine interaction, and because some of the excess quinidine deaths were non-cardiac (malignancy, suicide), it nevertheless highlighted the problem further examined prospectively, with variable outcomes, in studies such as CAST, CAST-II, IMPACT, EMIAT, CAMIAT, SWORD, and DIAMOND.
12. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32. • A retrospective analysis of antiarrhythmic drug treatment in 1330 patients enrolled in the SPAF study indicated > 2.5 fold increased mortality in those receiving antiarrhythmic drugs (primarily quinidine and procainamide), especially in the presence of heart failure.
13. Waldo AL, Camm AJ, DeRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
14. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med 1999;341:857-65.
15. Connolly SJ, Cairns J, Gent M, et al. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure - meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24. • A meta-analysis of EMIAT, CAMIAT, and other post-MI studies with amiodarone indicating a modest but demonstrable effect of the drug to reduce mortality.
16. Boutitie F, Boissel JP, Connolly SJ et al. Amiodarone interaction with beta-blockers : analysis of the merged EMIAT (European myocardial infarct amiodarone trial) and CAMIAT (Canadian amiodarone myocardial infarction trial) databases. Circulation 1999;99:2268-75.
17. Kr blocker and elevated plasma terfenadine concentrations resulting from inhibition of the drug's CYP3A4-mediated metabolism were thereby mechanistically linked to torsades de pointes.
18. Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990;322:1764-8. • This study demonstrated that a pharmacological response during drug treatment (β blockade with propafenone) is tightly linked to CYP 2D6 phenotype. with poor metaboliser subjects developing higher concentrations, and greater β blockade.
19. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-7. • This study used combined experiments in in vitro models and in genetically modified mice to implicate quinidine inhibition of digoxin transport by P-glycoprotein as a major mechanism underlying the effect of quinidine to elevate serum digoxin, recognised 20 years previously.
20. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-70.
21. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871-8.